Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO)

Virtu Financial LLC purchased a new position in Spero Therapeutics, Inc. (NASDAQ:SPRO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,046 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned 0.08% of Spero Therapeutics at the end of the most recent reporting period.

Separately, Monimus Capital Management LP purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $320,000. 25.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Spero Therapeutics

In other Spero Therapeutics news, CEO Sath Shukla sold 155,333 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $121,159.74. Following the sale, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at approximately $1,354,768.74. The trade was a 8.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ankit Mahadevia sold 69,219 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $53,990.82. Following the completion of the transaction, the director now owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 245,241 shares of company stock valued at $191,288. Company insiders own 4.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SPRO shares. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI downgraded shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a report on Friday, December 20th.

Spero Therapeutics Trading Down 3.6 %

Shares of SPRO opened at $0.69 on Wednesday. The company’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $1.04. The company has a market cap of $37.84 million, a P/E ratio of 9.92 and a beta of 0.68. Spero Therapeutics, Inc. has a twelve month low of $0.68 and a twelve month high of $1.81.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). The business had revenue of $15.04 million during the quarter, compared to analysts’ expectations of $12.40 million. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%. Analysts predict that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.